Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Holger Huisman"'
Autor:
Jonathan M. Coutinho, Lia Lucas Neto, Diana Aguiar de Sousa, Jorge Caria, Hans-Christoph Diener, Francesco Dentali, Corinna Miede, José M. Ferro, Adam Kobayashi, Martin Bendszus, Olav Jansen, Holger Huisman
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
International journal of stroke, 17(2). SAGE Publications Ltd
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
International journal of stroke, 17(2). SAGE Publications Ltd
Copyright © 2021 by World Stroke Organization.
Background: The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial. Methods: RE-SPECT CVT (ClinicalTrials.go
Background: The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial. Methods: RE-SPECT CVT (ClinicalTrials.go
Autor:
Francesco Dentali, José M. Ferro, Olav Jansen, Holger Huisman, Bas van der Veen, Jonathan M. Coutinho, Martin Bendszus, Adam Kobayashi, Jorge Caria, Hans-Christoph Diener, Corinna Miede
Publikováno v:
Stroke; a journal of cerebral circulation, 51(11), 3344-3347. Lippincott Williams and Wilkins
Background and Purpose: This analysis examined the frequency of dural arteriovenous fistulae (dAVF) after cerebral venous thrombosis (CVT) in patients included in a randomized controlled trial comparing dabigatran etexilate with dose-adjusted warfari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216c2f518f7396e3a887a38518a660b1
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85094932044
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85094932044
Autor:
Hans-Christoph Diener, Francesco Dentali, Simon Nagel, Andrey Alasheev, Jorge Caria, Mandy Frässdorf, José M. Ferro, José Mário Roriz, Laura Posthuma, Denis Karpov, Adam Kobayashi, Patrícia Canhão, Paul A. Reilly, Jonathan M. Coutinho, Holger Huisman
Publikováno v:
JAMA Neurology, 76(12), 1457-1465. American Medical Association
Importance Patients with cerebral venous thrombosis (CVT) are at risk of recurrent venous thrombotic events (VTEs). Non–vitamin K oral anticoagulants have not been evaluated in randomized controlled trials in CVT. Objective To compare the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::158cd12cde83ce6ed71ae3d3be7e2fe7
https://pure.amc.nl/en/publications/safety-and-efficacy-of-dabigatran-etexilate-vs-doseadjusted-warfarin-in-patients-with-cerebral-venous-thrombosis-a-randomized-clinical-trial(dc660951-e74e-4261-a25a-dea09afd6abc).html
https://pure.amc.nl/en/publications/safety-and-efficacy-of-dabigatran-etexilate-vs-doseadjusted-warfarin-in-patients-with-cerebral-venous-thrombosis-a-randomized-clinical-trial(dc660951-e74e-4261-a25a-dea09afd6abc).html
Autor:
Jorge Caria, Jonathan M. Coutinho, Hans-Christoph Diener, José M. Ferro, Marc Desch, Holger Huisman, Francesco Dentali, Adam Kobayashi, Mandy Fraessdorf
Publikováno v:
International journal of stroke, 13(7), 766-770. SAGE Publications Ltd
International Journal of Stroke, 13(7), 766-770. SAGE PUBLICATIONS LTD
International Journal of Stroke, 13(7), 766-770. SAGE PUBLICATIONS LTD
Rationale To prevent recurrent venous thrombotic events after acute cerebral venous or dural sinus thrombosis, guidelines recommend long-term oral anticoagulation with vitamin K antagonists. Non-vitamin K oral anticoagulant experience in cerebral ven
Autor:
Holger Huisman, Hans-Juergen Woerle, Russell Jones, Maximilian von Eynatten, Sanjay Patel, Anthony H. Barnett
Publikováno v:
The Lancet. 382:1413-1423
Summary Background A substantial proportion of patients with type 2 diabetes are elderly (≥65 years) but this group has been largely excluded from clinical studies of glucose-lowering drugs. We aimed to assess the effectiveness of linagliptin, a di
Autor:
Holger Huisman, S. Del Prato, Anthony H. Barnett, Klaus Dugi, Dietmar Neubacher, Hans-Juergen Woerle
Publikováno v:
Diabetes, Obesity and Metabolism. 13:258-267
Aim: To assess the safety and efficacy of the potent and selective dipeptidyl peptidase-4 inhibitor linagliptin 5 mg when given for 24 weeks to patients with type 2 diabetes who were either treatment-naive or who had received one oral antidiabetes dr
Autor:
Roland Buhl, Lars Groenke, A Veale, Kay Tetzlaff, Holger Huisman, Lorcan McGarvey, M Fležar, Lawrence Korducki, Stella Waitere-Wijker, Leif Bjermer, Alan Hamilton, Roger Abrahams, Jacques Hébert, Eric Derom
Publikováno v:
Pneumologie. 69
Autor:
Jim Reid, Henrik Watz, Holger Huisman, Roland Buhl, Gary T. Ferguson, Eric D. Bateman, Alan Hamilton, Stella Waitere-Wijker, Emilio Pizzichini, Lars Groenke, François Maltais, Kay Tetzlaff, Lawrence Korducki, Eric Derom
Publikováno v:
Pneumologie. 69
Introduction: Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD); olodaterol (O) is a once-daily long-acting β 2 -agonist that has re
Autor:
Kay Tetzlaff, Roland Buhl, Gary T. Ferguson, Alan Hamilton, Lars Grönke, Emilio Pizzichini, François Maltais, Lawrence Korducki, Jim Reid, Henrik Watz, Eric Derom, Stella Waitere-Wijker, Holger Huisman
Publikováno v:
Thorax. 69:A188-A189
Introduction Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD); olodaterol (O) is a once-daily long-acting β 2 -agonist that has rec
Autor:
R Abrahams, Lorcan McGarvey, Alan Hamilton, Kay Tetzlaff, Stella Waitere-Wijker, Roland Buhl, A Veale, M Fležar, Eric Derom, Jacques Hébert, Lars Grönke, Holger Huisman, Lawrence Korducki, Leif Bjermer
Publikováno v:
Thorax. 69:A189-A190
Introduction The fixed-dose combination (FDC) of tiotropium (T), a once-daily long-acting muscarinic antagonist, and olodaterol (O), a once-daily long-acting β 2 -agonist, is currently being evaluated in chronic obstructive pulmonary disease (COPD).